Milberg LLP announces that class action lawsuits were filed in the United States District Court for the Central District of California on behalf of purchasers of Peregrine Pharmaceuticals, Inc. (“Peregrine”) (NASDAQ: PPHM) common stock during the period July 16, 2012 to September 26, 2012, (the “Class Period”).
Milberg LLP has created a website ( http://www.PeregrineLawsuit.com) that seeks to answer common questions about shareholder class actions.
The Complaints allege violations of the federal securities laws against Peregrine and certain of its officers and directors for issuing materially false and misleading financial information.
On September 24, 2012, Peregrine disclosed that it had identified “major discrepancies” in the treatment group of the Phase II trial for its prospective lung cancer drug bavituximab and that investors should not rely on previously reported clinical data. In reaction to the news, Peregrine shares declined $4.23 per share or over 78%, to close at $1.16 per share on September 24, 2012.If you purchased Peregrine shares during the Class Period, you may, no later than November 27, 2012, request that the Court appoint you lead plaintiff of the proposed class. A lead plaintiff is a class member that represents other class members in directing the litigation. Your share in any recovery will not be affected by serving as a lead plaintiff, however, lead plaintiffs make important decisions that could affect the overall recovery for class members. You do not need to be a lead plaintiff to recover. You may retain Milberg LLP, or other attorneys, for this action, but do not need to retain counsel to recover. If this action is certified as a class action, class members will be automatically represented by Court-appointed counsel. The complaint in this action was not filed by Milberg. Milberg LLP has represented individual and institutional investors for over four decades and serves as lead counsel in Courts throughout the United States. Visit the Milberg website ( www.milberg.com) for more information about the firm. If you wish to discuss this matter with us, please contact the following attorneys: Andrei Rado, Esq.Milberg LLPOne Pennsylvania Plaza, 49th Fl.New York, NY 10119-0165Phone number: 800-320-5081Email: email@example.com Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV